In addition, several studies have demonstrated the efficacy of PPAR agonists to inhibit the progression of glomerulosclerosis [54] and have suggested that PPAR ligands have a direct beneficial renal effect. The gene discussed is PPARA; the disease is glomerulosclerosis.